Eupraxia Pharmaceuticals Stock EBITDA
Eupraxia Pharmaceuticals fundamentals help investors to digest information that contributes to Eupraxia Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eupraxia Pink Sheet. The fundamental analysis module provides a way to measure Eupraxia Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eupraxia Pharmaceuticals pink sheet.
Eupraxia |
Eupraxia Pharmaceuticals Company EBITDA Analysis
Eupraxia Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Eupraxia Pharmaceuticals EBITDA | (21.96 M) |
Most of Eupraxia Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eupraxia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Eupraxia Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (21.96 Million). This is 102.5% lower than that of the Healthcare sector and 121.93% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.56% higher than that of the company.
Eupraxia EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.Eupraxia Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Eupraxia Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 43.78 M | |||
| Shares Outstanding | 21.39 M | |||
| Shares Owned By Insiders | 12.40 % | |||
| Shares Owned By Institutions | 20.24 % | |||
| Price To Book | 3.89 X | |||
| EBITDA | (21.96 M) | |||
| Net Income | (22.99 M) | |||
| Cash And Equivalents | 35.46 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 9.26 M | |||
| Debt To Equity | 0.42 % | |||
| Current Ratio | 10.13 X | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | (14.64 M) | |||
| Earnings Per Share | (0.98) X | |||
| Number Of Employees | 19 | |||
| Market Capitalization | 78.89 M | |||
| Total Asset | 31.22 M | |||
| Z Score | 4.8 | |||
| Net Asset | 31.22 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Eupraxia Pink Sheet
If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |